Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2022-04-10T23:52:09Z | - |
dc.date.available | 2022-04-10T23:52:09Z | - |
dc.date.issued | 2021-11 | - |
dc.identifier.citation | JOURNAL OF CONTROLLED RELEASE, v. 338, Page. 211-223 | en_US |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0168365921004375 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/169829 | - |
dc.description.abstract | Despite the significant efforts in developing cancer vaccines, there are still numerous challenges that need to be addressed to ensure their clinical efficacy. Herein, a lymphatic dendritic cell (DC)-targeted artificial nanovaccine mimicking tumor cell membrane (ATM-NV) is developed to boost effector immune response and control immunosuppression simultaneously. The NVs are formulated with lipids, tumor cell membrane proteins, imi- quimod (IMQ), and IL-10 siRNA. IL-10 siRNA is incorporated to inhibit the secretion of IL-10, an immunosup- pressive cytokine, of maturated DCs upon IMQ. To enhance the DC targeting ability, the nanovaccine surface was non-covalently conjugated with the anti-CD205 antibody. The IMQ and IL-10 siRNA co-loaded, CD205 receptor- targeted artificial tumor membrane NVs (IMQ/siR@ATM-NVs) efficiently migrate to the tumor-draining lymph node and target DCs. Furthermore, immunization with IMQ/siR@ATM-NVs reduces the production of IL-10 and increases Th1-driven antitumor immunity resulted in a great tumor inhibition efficacy. Our results suggest a potential strategy to promote the vaccination's antitumor efficacy by blocking the intrinsic negative regulators in DCs. | en_US |
dc.description.sponsorship | This research was supported by National Research Foundation of Korea (NRF) grants funded by the Korea Government (MSIP) (No. 2018R1A2B2004668, 2021R1A2C3009556). The authors thank the Core Research Support Center for Natural Products and Medical Mate- rials (CRCNM) for technical support regarding the nano-indentation test. | en_US |
dc.language.iso | en | en_US |
dc.publisher | ELSEVIER | en_US |
dc.subject | Cancer vaccines | en_US |
dc.subject | Dendritic cells | en_US |
dc.subject | IL-10 | en_US |
dc.subject | Immunotherapy | en_US |
dc.subject | Melanoma | en_US |
dc.title | Nanovaccines silencing IL-10 production at priming phase for boosting immune responses to melanoma | en_US |
dc.type | Article | en_US |
dc.relation.volume | 338 | - |
dc.identifier.doi | 10.1016/j.jconrel.2021.08.031 | - |
dc.relation.page | 211-223 | - |
dc.relation.journal | JOURNAL OF CONTROLLED RELEASE | - |
dc.contributor.googleauthor | Phung, Cao Dai | - |
dc.contributor.googleauthor | Tran, Tuan Hiep | - |
dc.contributor.googleauthor | Nguyen, Hanh Thuy | - |
dc.contributor.googleauthor | Nguyen, Tien Tiep | - |
dc.contributor.googleauthor | Jeong, Jee-Heon | - |
dc.contributor.googleauthor | Ku, Sae Kwang | - |
dc.contributor.googleauthor | Yong, Chul Soon | - |
dc.contributor.googleauthor | Choi, Han-Gon | - |
dc.contributor.googleauthor | Kim, Jong Oh | - |
dc.relation.code | 2021004235 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.